Laid off from Replimune.

What Replimune layoffs have meant for employees

The cuts at Replimune follow a single regulatory decision. The company was still clinical stage when the FDA's second rejection letter arrived following a first in July 2025, and its April 10 release quoted the chief executive saying RP1 wouldn't be viable without a timely accelerated approval. A spokesperson told the Worcester Business Journal the layoffs were directly tied to that rejection, which the spokesperson said put the entire company at risk, and that Replimune had stopped its compassionate use program and adjusted the planned expansion of its Phase 3 trial program.

Replimune's annual report, filed in June, said everyone affected by the April plan had been told. For the people who stayed, it also warned that another reduction might follow without a near-term approval, the same approval Patel had said RP1 needed to stay viable. That approval came on August 6, when the FDA cleared the same therapy under a new name, TUDRIQEV, according to the company's August 6 release.

Replimune's quarterly report for the quarter that ran from July through September says the restructuring took the entirety of the commercial team, and that rehiring didn't ramp back up until later in that quarter, after the approval. Its risk disclosures add that the company has begun to rebuild its sales, marketing and commercialization teams and may face challenges in rehiring former staff. On the October 28 call, Patel said the sales force had nothing left but training and account work, with a couple of internal positions still being filled. If Replimune has approached you about coming back, the drug's approval is conditional, since the August release says continued approval may depend on a confirmatory trial.

Patel's April statement singled out manufacturing, saying the job cuts would include substantially scaling back U.S. manufacturing, and the second set of notices covered jobs at the plant on New York Avenue in Framingham. The plant itself was still operating in June, when the same annual report described the company's in-house manufacturing facility in Framingham and its job of supplying clinical studies and, if a drug was approved, its commercial launch. On the same October call, Patel said Replimune had more than a year of inventory on hand, made at its in-house plant. The rehiring accounts from August through October all describe the commercial team, and none of them mentions the plant.

The Massachusetts notices may not hold everyone who was cut. The annual report's share works out to about 255 positions by our arithmetic, more than those notices list, and the same report describes fully remote employees and an office in the United Kingdom alongside Woburn and the plant. So if you worked remotely or overseas, your job may not appear in those notices, which cover the Woburn and Framingham sites, while the annual report's percentage counts the whole company.

For anyone explaining the gap to a hiring manager, the cause is public. The annual report calls the restructuring a result of the FDA's letter, Patel said the same day the letter was announced that jobs would go, and Patel's statement closed with the line "Not because the medicine failed. Because the system did." A short version, if you want one, is "the FDA rejected our lead drug in April, and the company made cuts across the business." If the question keeps coming up in interviews, how to explain a layoff works through ways to answer it. All three notices went to Massachusetts, whose rules for an unemployment claim are laid out in Massachusetts unemployment benefits. Anyone whose Replimune health plan ended with the cuts can find what continuing it involves in how COBRA works.